- Zacks Small Cap Research•11 days ago
Certain Catalysts Expected to Return ICAD (ICAD) to Positive Revenue Growth in 20172016 has been a disappointing year in terms of revenue. Therapy revenue through the first nine months of the year is down 66%, largely as a result of the unfavorable change to reimbursement of non-melanoma skin cancer. Detection revenue has fared much better, but is still down over 13% over the same period and has been hampered by the loss of iCAD’s (ICAD) MRI distribution agreement (as of August 2015). And delays to FDA clearance and U.S. launch of the 3D tomosynthesis product have also trimmed Detection revenue expectations for 2016. - 3D Tomosynthesis; We think tomo could be a big winner for ICAD given the criticism and debate over the utility of stand-alone mammography and increased demand for more accurate detection of breast cancer. Radiologists are regularly demanding system upgrades from 2D to 3D due to the latter’s proven ability to improve cancer detection rates, reduce recall rates, shorten reading time and lessen reading fatigue. This has resulted in a swift transition to 3D tomosynthesis. Armed with clinical studies demonstrating the benefits of 3D tomo, ICAD is looking to capitalize on this industry shift.
- Accesswire•3 months ago
LOS ANGELES, CA / ACCESSWIRE / November 30, 2016 / iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification ...
- PR Newswire•3 months ago
NASHUA, N.H. and CHICAGO, Nov. 28, 2016 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early detection ...
ICAD : Summary for icad inc. - Yahoo Finance
iCAD, Inc. (ICAD)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.24 x 100|
|Ask||4.98 x 200|
|Day's Range||3.59 - 3.89|
|52 Week Range||2.82 - 6.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|